THE DISCLOSURE RELATES TO A COMPOSITION COMPRISING ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AT LEAST ONE POLY (LACTIDE-CO-GLYCOLIDE) (PLGA); AND AT LEAST ONE FATTY ACID, WHEREIN THE AT LEAST ONE FATTY ACID IS AT LEAST 0.5% IN WEIGHT RELATIVE TO THE TOTAL WEIGHT OF THE COMPOSITION. THE COMPOSITION AS DISCLOSED HEREIN HAS SIGNIFICANTLY REDUCED BURSE RELEASE EFFECT. THE DISCLOSURE ALSO PROVIDES A METHOD OF TREATING PARKINSON’S DISEASE COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF THE COMPOSITION AS DISCLOSED TO A SUBJECT IN NEED THEREOF.